POSTED BY CARA SCHILLINGER ON 7/9/2012
A Placebo-Controlled Randomized Trial of Warfarin in
Idiopathic Pulmonary Fibrosis
Imre Noth1, Kevin J. Anstrom2, Sara Bristol Calvert2, Joao de Andrade3, Kevin R. Flaherty4,
POSTED BY CARA SCHILLINGER ON 7/5/2012
STOCKHOLM, June 28, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has included Esbriet® (pirfenidone) on Sweden's list of reimbursed drugs, making Esbriet the first medicine for the treatment of idiopathic pulmonary fibrosis (IPF) to be reimbursed in Sweden.